Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies)
- PMID: 11053681
- DOI: 10.1016/s0960-8966(00)00143-7
Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies)
Abstract
Dysferlin is the protein product of the gene (DYSF) that is defective in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy. Calpain 3 is the muscle-specific member of the calcium activated neutral protease family and primary mutations in the CAPN3 gene cause limb girdle muscular dystrophy type 2A. The functions of both proteins remain speculative. Here we report a secondary reduction in calpain 3 expression in eight out of 16 patients with a primary dysferlinopathy and clinical features characteristic of limb girdle muscular dystrophy type 2B or Miyoshi myopathy. Previously CAPN3 analysis had been undertaken in three of these patients and two showed seemingly innocuous missense mutations, changing calpain 3 amino acids to those present in the sequences of calpains 1 and 2. These results suggest that there may be an association between dysferlin and calpain 3, and further analysis of both genes may elucidate a novel functional interaction. In addition, an association was found between prominent expression of smaller forms of the 80 kDa fragment of laminin alpha 2 chain (merosin) and dysferlin-deficiency.
Similar articles
-
Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes.Arch Neurol. 2007 Aug;64(8):1176-82. doi: 10.1001/archneur.64.8.1176. Arch Neurol. 2007. PMID: 17698709
-
Dysferlin protein analysis in limb-girdle muscular dystrophies.J Mol Neurosci. 2001 Aug;17(1):71-80. doi: 10.1385/JMN:17:1:71. J Mol Neurosci. 2001. PMID: 11665864
-
[Dysferlin deficiency: the cause of limb-girdle muscular dystrophy 2B and Miyoshi myopathy in a Chinese pedigree].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004 Apr;21(2):128-31. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004. PMID: 15079794 Chinese.
-
Dysferlinopathies: Clinical and genetic variability.Clin Genet. 2022 Dec;102(6):465-473. doi: 10.1111/cge.14216. Epub 2022 Sep 6. Clin Genet. 2022. PMID: 36029111 Review.
-
Limb-Girdle Muscular Dystrophy 2B and Miyoshi Presentations of Dysferlinopathy.Am J Med Sci. 2017 May;353(5):484-491. doi: 10.1016/j.amjms.2016.05.024. Epub 2016 May 30. Am J Med Sci. 2017. PMID: 28502335 Review.
Cited by
-
Translational research and therapeutic perspectives in dysferlinopathies.Mol Med. 2011 Sep-Oct;17(9-10):875-82. doi: 10.2119/molmed.2011.00084. Epub 2011 May 6. Mol Med. 2011. PMID: 21556485 Free PMC article. Review.
-
Myopathy caused by anoctamin 5 mutations and necrotizing vasculitis.J Neurol. 2012 Sep;259(9):1988-90. doi: 10.1007/s00415-012-6502-x. Epub 2012 Apr 19. J Neurol. 2012. PMID: 22527239 No abstract available.
-
From proteins to genes: immunoanalysis in the diagnosis of muscular dystrophies.Skelet Muscle. 2011 Jun 24;1(1):24. doi: 10.1186/2044-5040-1-24. Skelet Muscle. 2011. PMID: 21798100 Free PMC article.
-
The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments.Biomolecules. 2024 Feb 21;14(3):256. doi: 10.3390/biom14030256. Biomolecules. 2024. PMID: 38540676 Free PMC article. Review.
-
Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy.PLoS One. 2011;6(12):e29061. doi: 10.1371/journal.pone.0029061. Epub 2011 Dec 16. PLoS One. 2011. PMID: 22194990 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical